Clinical Trials Logo

Clinical Trial Summary

Cerebral venous thrombosis is considered as a rare type of stroke with an annual incidence of 3 to 4 per million people. It occurs generally in young patients (mean age of occurrence = 40 years) and principally in young females (75%) generally in pregnancy or oral contraceptive use situations.

The onset may be acute (less than 2 days), subacute (between 2 and 30 days) or chronic (more than 30 days). The clinical presentation is highly variable and includes patients with only a mild headache, others with focal neurological deficits and a few with a dramatic syndrome and a coma. Moreover the evolution can be very different with unpredictable outcome: more often it is favorable with a low mortality rate, but in some cases it can be a worse course. The aim of this study is to evaluate the correlation of some biological markers: thrombin generation test and D-Dimers (marker of fibrin generation and degradation) with the type of onset or the wide spectrum of clinical presentations or the different modes of evolution.

All patients over 16 years ago may be included in the program when CVT diagnosis is proved by magnetic resonance angiography (MRA). For each included patient, there are four blood assays: the first just at the time of diagnosis and before the beginning of treatment, the second before the beginning of the oral anticoagulant treatment. The third assay is done in the third month at the time of a MRA. The last assay is made one month after the end of the anticoagulant treatment or in 12th month after the beginning of the disease if the treatment goes on.

For each sample, the investigators perform a thrombin generation test and a D-Dimers measurement.


Clinical Trial Description

n/a


Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT02013635
Study type Observational
Source University Hospital, Rouen
Contact
Status Completed
Phase N/A
Start date July 2011
Completion date September 2016

See also
  Status Clinical Trial Phase
Completed NCT00924859 - The Role of Factor XIII Activation Peptide and D-dimer Values for the Diagnosis of Cerebral Venous Thrombosis (CVT)
Recruiting NCT03747081 - Efficacy Comparison of Warfarin Versus Rivaroxaban CVT Phase 1/Phase 2
Recruiting NCT03217448 - The Efficacy and Safety of Dabigatran Etexilate for the Treatment of Cerebral Venous Thrombosis Phase 3
Recruiting NCT04660747 - Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis
Completed NCT03178864 - Study of Rivaroxaban for CeREbral Venous Thrombosis Phase 2
Recruiting NCT04972058 - Philippine Neurological Association One Database - Stroke
Completed NCT06266585 - Clinical Deterioration in Cerebral Venous Thrombosis: A Predictive Study
Completed NCT05990894 - Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.
Completed NCT03033966 - Evaluation of Cerebral Oxygenation and Hemodynamics in Patients With Cerebral Venous Thrombosis N/A
Not yet recruiting NCT03191305 - Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous Thrombosis N/A
Recruiting NCT05491980 - Florida Cerebrovascular Disease Biorepository and Genomics Center
Completed NCT01796015 - Intracranial Hypertension and Optic Nerve Sheath Diameter N/A